Author name: Leonardo Arias

J&J still holds the top deal of the year by value with its $14.6 billion buy of Intra-Cellular in January, but the next four biggest acquisitions came in the past four months.

As major pharmas pull away from the U.K. and the U.S. risks ceding its lead through a national brain drain, the U.K. must create a new, more robust model for innovation.

A new analysis from SRS Acquiom puts into perspective the headline values seen when a company announces a backloaded M&A deal. Biotechs have much on the line when they agree to deals with massive potential but little upfront.

The two most historically deal-conservative Big Pharmas have the most money to play with for a major M&A transaction, according to a recent Stifel analysis.

Talks between pharma and successive U.K. governments have failed to deliver the market access terms that the industry wants, contributing to a pullback in investment.

Pfizer CEO Albert Bourla directly credited the threat of tariffs with leading to the deal, in which the company will offer drugs on a soon-to-be-launched website called TrumpRx.

A shutdown would hit the massive federal healthcare department’s agencies differently. For example, the CMS would lose 47% of its staff, while the CDC and the NIH would lose 64% and 75%, respectively.

The agency estimates that about 86% of staff can remain in the event that funding stops, but new drug applications cannot be accepted.

In this discussion, our guests give their observations and recommendations on how companies can navigate within the United States market and beyond. Watch now.

More than 50 medical groups have signed on to letters calling for healthcare workers to be exempt from new H-1B visa fees, warning the increased costs could cripple vital overseas recruitment.